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ZD6126 is a vascular targeting agent that disrupts the tubulin cytoskeleton of proliferating neo-endothelial cells. This leads to the
selective destruction and congestion of tumour blood vessels in experimental tumours, resulting in extensive haemorrhagic necrosis.
In this study, the dose-dependent activity of ZD6126 in rat GH3 prolactinomas and murine RIF-1 fibrosarcomas was assessed using
two magnetic resonance imaging (MRI) methods. Dynamic contrast-enhanced (DCE) MRI, quantified by an initial area under the
time–concentration product curve (IAUC) method, gives values related to tumour perfusion and vascular permeability. Multigradient
recalled echo MRI measures the transverse relaxation rate T  
2 , which is sensitive to tissue (deoxyhaemoglobin). Tumour IAUC and
R  
2 (¼ 1=T  
2 ) decreased post-treatment with ZD6126 in a dose-dependent manner. In the rat model, lower doses of ZD6126
reduced the IAUC close to zero within restricted areas of the tumour, typically in the centre, while the highest dose reduced the
IAUC to zero over the majority of the tumour. A decrease in both MRI end points was associated with the induction of massive
central tumour necrosis measured histologically, which increased in a dose-dependent manner. Magnetic resonance imaging may be
of value in evaluation of the acute clinical effects of ZD6126 in solid tumours. In particular, measurement of IAUC by DCE MRI should
provide an unambiguous measure of biological activity of antivascular therapies for clinical trial.
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A functioning vascular network is a prerequisite for tumour
growth, providing tumour cells with a nutritive blood supply and
facilitating the removal of toxic waste products of metabolism. It is
well known that the architecture of tumour blood vessels differs
considerably from that of normal tissues (Denekamp, 1993). For
example, tumour blood vessels contain a significant component of
proliferating, immature endothelium, in contrast to the quiescent
endothelium found in most normal adult tissues. The continued
expression of proangiogenic growth factors in tumours can result
in an endothelial cell proliferation rate 35-fold higher than that of
normal tissues (Denekamp and Hobson, 1982). Novel anticancer
therapies are being developed to exploit differences between
normal and tumour endothelium, with the aim of selectively
targeting the destruction of tumour endothelium while leaving
normal blood vessels relatively unaffected (Dark et al, 1997). This
approach is particularly attractive since the destruction of one
tumour blood vessel has the potential to kill many dependent
tumour cells (Chaplin and Dougherty, 1999).
ZD6126 is a novel vascular targeting agent that has been
shown to have significant antitumour activity against a broad
range of human xenografts in rodent model systems, including
early-phase lung cancer metastases (Blakey et al, 2002;
Davis et al, 2002; Goto et al, 2002). Previous work in mice and
rats has shown that ZD6126 is rapidly converted by serum
phosphatase activity to N-acetylcolchinol (NAC), a tubulin bind-
ing agent that inhibits tubulin polymerisation and causes
microtubule destabilisation.
Studies of cultured human endothelial cells in vitro have
demonstrated that NAC disrupts the tubulin cytoskeleton and
produces rapid changes in endothelial cell morphology at
noncytotoxic concentrations. Moreover, these effects are selective
for proliferating compared with confluent endothelial cells. In vivo,
within an hour of ZD6126 administration, there is evidence of
exposure of the basal lamina of tumor blood vessels, with
retraction and subsequent loss of endothelial cells (Blakey et al,
1999). These early changes are followed by thrombosis and vessel
occlusion resulting in extensive central tumour necrosis 24h
after ZD6126 treatment. The vascular targeting activity of ZD6126
was seen at doses 1/8 to 1/16 of the maximum well-tolerated dose,
and was selective for tumor blood vessels, with no evidence of
similar effects in the vessels of surrounding normal tissues (Blakey
et al, 2002; Davis et al, 2002). A consistent observation from
preclinical models is that a thin rim of tumour cells at the edge of
the tumour mass survives treatment with ZD6126, presumably
because these cells are fed from unaffected vessels in the
surrounding normal tissues, although there is no direct evidence
for this.
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sThe clinical development of novel antivascular therapies
requires the development and validation of quantitative end
points that are associated with tumour blood vasculature and its
response, and that can be translated to the clinic. Magnetic
resonance imaging (MRI) is one approach that affords such
biomarkers of response to antivascular therapies, and drug efficacy
has been demonstrated in both preclinical (Beauregard et al, 2002;
Maxwell et al, 2002) and clinical studies (Dowlati et al, 2002;
Galbraith et al, 2002). In this study, we describe the use of two MRI
techniques for the noninvasive assessment of the dose-dependent
antivascular activity of ZD6126 on tumour perfusion. In the first
study, dose–response to ZD6126 in rat GH3 prolactinomas was
determined using dynamic contrast-enhanced (DCE) MRI, in
which the tumour uptake of exogenously administered Gd-DTPA-
BMA (gadolinium diethylenetriamine penta-acetic acid bismethyl-
amide or gadodiamide) is monitored (Evelhoch, 1999). In a second
study, multi-gradient recalled echo (MGRE) MRI was used to
assess efficacy of ZD6126 in two rodent tumour models, rat GH3
prolactinomas and murine RIF-1 fibrosarcomas. MGRE MRI
allows quantification of the transverse relaxation rate R  
2
(¼ 1=T  
2 ), which is dependent on the tissue deoxyhaemoglobin
concentration (Abramovitch et al, 1999; Kostourou et al, 2002).
METHODS
Animals and tumours
All experiments were performed in accordance with the local
ethical review panel, the UKCCCR guidelines (Workman et al,
1998) and the UK Home Office Animals Scientific Procedures Act,
1986. The data were accrued from two rodent tumour models, the
rat GH3 prolactinoma grown s.c. in the flanks of female Wistar
Furth rats (Prysor-Jones and Jenkins, 1981) and the murine RIF-1
fibrosarcoma grown s.c. in the flanks of female C3H mice
(Twentyman et al, 1980). Anaesthesia was induced with a 4mlkg
 1
(rat) or 10mlkg
 1 (mouse) intraperitoneal injection of fentanyl
citrate (0.315mgml
 1) plus fluanisone (10mgml
 1) (‘Hypnorm’,
Janssen Pharmaceutical Ltd, High Wycombe), midazolam
(5mgml
 1) (‘Hypnovel’, Roche, Welwyn Garden City) and water
(1:1:2). This anaesthetic mixture has been shown to have a
minimal effect on tumour blood flow (Menke and Vaupel, 1988).
Tumour volume was measured using calipers, assuming an
ellipsoidal shape.
Formulation, administration and dosing of ZD6126
ZD6126 (N-acetylcolchinol-O-phosphate) was formulated in 20%
of 5% sodium carbonate and 80% phosphate-buffered saline
yielding a clear solution at BpH 7, and was rapidly administered
intravenously as a bolus injection via a tail vein. Control animals
were treated with vehicle alone. Doses of 12.5, 25 or 50mgkg
 1
ZD6126 for rats and 100 or 200mgkg
 1 ZD6126 for mice were
used which, when taking into account the surface law formula, are
similar and well-tolerated host dose regimes (Blakey et al, 2002).
Dynamic contrast-enhanced MRI
The dose–response of rat GH3 prolactinomas to ZD6126 was
determined using DCE MRI, performed 24h prior to and 24h post-
treatment with phosphate-buffered saline (n¼6), 12.5mgkg
 1
(n¼5), 25mgkg
 1 (n¼5) or 50mgkg
 1 (n¼5) ZD6126 adminis-
tered intravenously. The mean tumour volume for this study was
3.4970.3cm
3 (range 2.54–5.38cm
3). Rats were anaesthetised, a
butterfly catheter inserted into a tail vein for contrast agent
administration, and placed supine into a 63mm quadrature
birdcage coil. Image sets were acquired on a Varian Unity Inova
system interfaced to a 4.7T horizontal magnet from four
contiguous 2mm slices through the tumour and one through the
abdomen to provide a muscle tissue reference, using a spin-echo
sequence with repetition time TR¼120ms, echo time TE¼10ms
and a 128 128 matrix, giving an acquisition time of 15.4s per
image set. Prior to DCE MRI, spin-echo images were acquired from
the same slices and with the same field of view and spatial
resolution as the time course data to provide baseline T1 data. The
images were acquired with TE¼120ms and TR¼0.12, 0.5, 2 and
10s. In some cases, these data were either missing or were too
noisy, so mean data from the remainder of the cohort were used.
The mean baseline R1 (¼1/T1) obtained was 0.5370.07s
 1
(mean7s.d.). Since the change in R1 in well-vascularised pixels
was typically three times this value, it is unlikely that serious
errors were introduced by the use of this mean value. Five
image sets were acquired prior to and 40 sets after bolus injection
of 0.1mmolkg
 1 gadodiamide (Gd-DTPA-BMA) (Omniscan,
Amersham Health, Little Chalfont). The total DCE MR imaging
time postinjection was 10min 15s.
Data were transferred and processed in software developed
by the authors (JJT, DJOM), and running under IDL 5.3/5.4
(Research Systems, Boulder, CO, USA). For each tumour slice,
a region-of-interest (ROI) was drawn over the whole tumour,
but excluding the surrounding skin/muscle. A similar ROI was
drawn over back muscle in the abdominal slice. The five
preinjection images were averaged to increase signal-to-noise
ratio and subtracted from the postinjection images to give
enhancement images. Tumour and muscle T1 time courses
were calculated on a pixel-by-pixel basis from the enhancement
and baseline T1 values and converted to gadodiamide concentra-
tions using the known relaxivity of gadodiamide. The initial
area under the time–concentration product curve (IAUC)
for the first 150s after administration of gadodiamide was then
integrated, and the tumour data normalised to the median
muscle IAUC to account for differences in the arterial input
function between animals (Evelhoch, 1999). This methodology
has been endorsed for use in studies of antivascular agents
(Leach et al, 2003). The data were reviewed blind as images and
normalised IAUC frequency histograms. Tumour IAUC values
greater than the muscle median IAUC were defined as highly
enhancing pixels. This threshold was not chosen to distinguish
muscle and tumour, but to define regions of tumour that did
not enhance significantly. The choice of this cutoff point for
the highly enhancing fraction was validated by cumulative
histogram analysis of the change in highly enhancing fraction
with treatment. Statistical analysis of the changes induced by
ZD6126 treatment were based on the change in the proportion of
highly enhancing pixels.
After DCE MRI, the tumours were excised, fixed in formal saline,
cut in the same plane/orientation as for the MRI, and stained with
haematoxylin and eosin. Tissue sections were assessed for
necrosis, using a scale from grade 1 (0–10% necrosis) to grade
10 (490–100% necrosis) (Blakey et al, 2002). The necrosis scores
represent the median value of five sections for each tumour at each
dose level.
Multi-gradient recalled echo MRI
ZD6126 was administered intravenously to rats bearing GH3
prolactinomas (0, 25 or 50mgkg
 1) and mice bearing RIF-1
fibrosarcomas (0, 100 or 200mgkg
 1)( n¼3 per treatment group).
The mean tumour volume for the rat GH3 prolactinomas was
3.6170.41cm
3 (range 2.92–4.3cm
3), and for the murine RIF-1
fibrosarcomas was 0.770.13cm
3 (range 0.53–0.91cm
3).
1H MRI
was performed 24h later at 4.7T using a 3-turn, 25mm coil for rats
or a 2-turn 12mm coil for mice. The anaesthetised animals were
positioned so that the tumour hung vertically into the radio-
frequency coil and covered with a warm water blanket to maintain
the core temperature at 371C. Field homogeneity was optimised by
shimming on the water signal for each tumour to a linewidth of
30–50Hz.
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sFive 1mm thick transverse slices through the tumour were
identified by
1H MR scout images. Multi-gradient recalled echo
images were then acquired from these slices; a train of eight echoes
was acquired with a repetition time of 80ms, initial echo of 5ms
and an echo spacing of 5ms, resulting in sets of images with
increased T  
2 weighting. The total imaging time was ca 14min.
Tumour R  
2 (¼ 1=T  
2 ) maps for each slice were generated using all
eight gradient-echo image sets by fitting an exponential model on a
pixel-by-pixel basis. For each slice, R  
2 was determined from an
ROI encompassing the whole tumour but excluding the surround-
ing skin/muscle, and the mean R  
2 for each tumour determined
from all five slices (Howe et al, 1999; Robinson et al, 2001). After
MGRE MRI, the tumours were excised and assessed blind for
necrosis by histology as before.
Significance testing
The use of MRI for the noninvasive assessment of tumour response
to ZD6126 means that each animal serves as its own control. This
harnesses significant statistical power through the use of paired
tests, while minimising the number of animals required per cohort.
Results are presented in the form: mean71 s.e.m. Significance
testing employed the two-sided Mann–Whitney U-test for
nonparametric data.
RESULTS
Dynamic contrast-enhanced MRI study
Visual inspection of DCE-MRI images showed that the highest
dose of 50mgkg
 1 ZD6126 essentially eliminated contrast uptake
in the centre of GH3 tumour, the highly enhancing tissue being
largely confined to the rim 24h post-treatment. Magnetic
resonance images acquired from one representative slice of a
GH3 prolactinoma prior to and post-treatment with this highest
dose are shown in Figure 1A. For all the tumours studied, the
pretreatment images were heterogeneous, reflecting the hetero-
geneity in background necrosis in this tumour model (40–50%
necrotic fraction). Example normalised IAUC frequency histo-
grams obtained from a rat prior to and post-treatment with the
highest dose of 50mgkg
 1 are shown in Figure 1B. In the control
tumours, a slight, nonsignificant shift towards lower IAUC was
apparent, which may reflect tumour growth over 48h. The between
and within subject coefficient of variation of the fraction of highly
enhancing pixels in the pretreatment tumours was 26 and 17%,
respectively. In all, 14 of the 15 tumours treated with ZD6126
showed a reduction in the highly enhancing fraction. At lower
doses of ZD6126, this response was heterogeneous, with some
tumour regions being profoundly affected while others appeared
spared. At 50mgkg
 1 ZD6126, the highly enhancing fraction
was limited to the periphery of the tumour post-treatment. This is
clearly evident in Figure 1A. Note also the characteristic spike at
very low IAUC observed in the frequency histogram of the treated
tumour.
Figure 2A shows haematoxylin and eosin stained sections of
control and ZD6126-treated GH3 tumours 24h after drug
treatment. Essentially, the darker stain represents more viable
tissue. ZD6126 caused massive central tumour necrosis in a dose-
dependent manner, the central necrotic core being surrounded by
a viable rim of tumour cells.
The dose–response of GH3 prolactinomas to ZD6126 is
summarised in Figure 3. ZD6126 induced a decrease in the highly
enhancing fraction of GH3 prolactinomas in a dose-dependent
manner, and this response was highly significant at 25 and
50mgkg
 1. Histological analysis of these same tumours showed
that the median necrosis score increased in a dose-dependent
manner, significantly at 25 and 50mgkg
 1.
Multi-gradient recalled echo MRI study
Calculated tumour T  
2 maps from one control GH3 prolactinoma
and RIF-1 fibrosarcoma, and one ZD6126-treated GH3 and RIF-1
tumour are shown in Figure 4. Tumour R  
2 (¼ 1=T  
2 ) decreased
with treatment. Figure 2B shows haematoxylin and eosin stained
sections of a control and ZD6126-treated RIF-1 tumour 24h after
drug treatment. The control RIF-1 tumours were more viable
(o10% necrotic fraction) than the control GH3 tumours. In both
tumour models, ZD6126 caused massive central tumour necrosis
in a dose-dependent manner, the central necrotic core being
surrounded by a viable rim of tumour cells (Figure 2). The
reduction of R  
2 was associated with the induction of extensive
central necrosis induced by ZD6126, as measured by histology. The
results of this study are summarised in Table 1.
DISCUSSION
The development and validation of quantitative, clinically applic-
able MRI end points to assess parameters associated with tumour
vasculature is critical for determining the activity of vascular-
targeting agents, where access to tumour tissue following therapy
is not usually possible. Preclinical models have shown that a single
dose of ZD6126 demonstrates significant antitumour activity,
causing extensive tumour necrosis, but that this does not
necessarily translate into a significant growth delay in human
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Figure 1 (A) Representative T1-weighted images acquired from one
slice of a GH3 prolactinoma prior to and post-treatment with 50mgkg
 1
ZD6126. The highly enhancing fraction was clearly limited to the periphery
of the tumour post-treatment. (B) Normalised IAUC frequency histograms
obtained from the same tumour prior to (—) and post-treatment with
50mgkg
 1 ZD6126 (–– ), acquired as part of the DCE MRI dose–
response study. Note the characteristic spike at very low IAUC of the
treated tumour group.
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stumour xenografts (Blakey et al, 2002; Davis et al, 2002). Primarily,
this appears to be because of rapid regrowth from viable cells at
the rim of the tumour mass. Therefore, noninvasive measures of
tumour vascular function are required to examine the activity of
ZD6126 in the clinic. Here, we have demonstrated the use of DCE
and MGRE MRI to measure the effects of changes in tumour
perfusion of transplanted rat GH3 prolactinomas and murine
RIF-1 fibrosarcomas, in order to noninvasively assess the
dose-dependent tumour vascular-targeting activity of ZD6126.
We have also provided validation of these methods by examining
the induction of tumour necrosis by histology.
The dose–response of rat GH3 prolactinomas to ZD6126 was
measured using DCE MRI and histological assessment of necrosis.
Incorporation of a reference muscle tissue permitted an accurate
assessment of the tumour IAUC, without direct measurement of
the arterial input function. This approach was used to monitor the
effects of ZD6126 on the perfusion of GH3 prolactinomas. The
proportion of highly enhancing pixels within the tumour was
significantly reduced in a dose-dependent manner by ZD6126.
These data are consistent with the tumour vasculature being
compromised by ZD6126 and subsequent induction of necrosis,
which, according to histological analysis, increased in a dose-
dependent manner. Lower doses of ZD6126 (12.5–25mgkg
 1)
reduced the IAUC close to zero within restricted areas of the
tumour, typically in the centre of the tumour, while the IAUC
remained at pretreatment levels elsewhere. The highest dose
(50mgkg
 1) reduced the IAUC to zero over the majority of the
tumour. This heterogeneous response contrasts with the response
seen with other therapeutic approaches to the tumour vasculature,
for example, inhibition of VEGF signalling, where the histogram
shifts to the left but the shape remains unchanged (Checkley et al,
1999, 2001).
Activity of ZD6126 against rat GH3 prolactinomas and murine
RIF-1 fibrosarcomas was also evaluated by MGRE MRI. Multi-
gradient recalled echo MRI allows the quantification of the
transverse relaxation rate R  
2 in an efficient and accurate manner.
Furthermore, it is completely noninvasive, relying on intrinsic
susceptibility contrast mechanisms rather than injection of a
contrast agent. An increase in R  
2 may reflect an increase in the
tissue content of paramagnetic Fe species, primarily deoxyhae-
moglobin within erythrocytes (Thulborn et al, 1982), consistent
with a reduction in tissue perfusion. Conversely, a decrease in R  
2
is consistent with increased tissue water associated with oedema or
necrosis. We hypothesised that following treatment with ZD6126,
haemoglobin within erythrocytes would deoxygenate, resulting in
an increase in R  
2 . This hypothesis was not supported by the data,
which showed a decrease in R  
2 24h after treatment.
Tumour R  
2 can be related to tissue vascularity and blood
oxygenation by (Howe et al, 2001)
R  
2 ¼ A:BV:Hct:½dHb þR  
2tissue
where A is a constant dependent on blood vessel size and
distribution, BV is the fractional blood volume, Hct the
haematocrit, [dHb] the blood deoxyhæmoglobin concentration
Control
Control 200 mg kg
−1
50 mg kg
−1
A
B
Figure 2 Haematoxylin and eosin stained sections of (A) a control and
ZD6126-treated GH3 prolactinoma and (B) a control and ZD6126-
treated RIF-1 fibrosarcoma. Essentially, the darker stain represents more
viable tissue. Note that the control GH3 has a larger necrotic fraction
compared to the control RIF-1, which is largely viable. ZD6126 caused
massive central tumour necrosis, the central necrotic core being
surrounded by a viable rim of tumour cells.
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Figure 3 Dose–response of GH3 prolactinomas to ZD6126 assessed
by (A) necrosis and (B) DCE MRI. Treatment with ZD6126 induced a
decrease in the mean fraction of highly enhancing pixels in the GH3
prolactinomas in a dose-dependent manner, which was highly significant at
25 and 50mgkg
 1 (**Po0.02, Mann–Whitney two-tailed U-test).
Associated with this response was an increase in tumour necrosis in a
dose-dependent manner (m), which was also significant at 25 and
50mgkg
 1 (*Po0.05, ***Po0.01, Mann–Whitney two-tailed U-test).
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sand R  
2tissue the intrinsic contribution of the tissue to the tumour
R  
2 . The decrease in tumour R  
2 that we measured could be
because of one of several factors. ZD6126 induces thrombosis and
congestion of erythrocytes in tumour blood vessels 24h after
treatment resulting in extensive central tumour necrosis (Blakey
et al, 2002; Davis et al, 2002). As the erythrocytes coagulate they
must become deoxygenated, thereby causing an increase in [dHb],
and hence an increase in R  
2 . However, if there is an agglomeration
of erythrocytes into small focal areas (Tozer et al, 2001), then the
average field inhomogeneity could be decreased, causing a
reduction in A that more than compensates for the [dHb] increase,
decreasing R  
2 . There could also be vessel collapse prior to
necrosis, which would decrease R  
2 via the term BV. Lastly, any
oedema formed, which may be more fluid than viable tumour
tissue, would cause a decrease in R 
2tissue. Although further work is
needed to elucidate the exact mechanisms responsible, a change in
tumour R  
2 measured by MGRE MRI may be a simple and
convenient alternative end point for detecting acute changes
induced by antivascular therapies.
Histological assessment of ZD6126-treated tumours showed
massive necrosis in the centre of the tumour while the peripheral
tissue remained viable. This response pattern has been commonly
observed in a wide range of different rodent tumour models with
both ZD6126 (Blakey et al, 2002; Davis et al, 2002) and other
antivascular therapies (Tozer et al, 2001). Despite ZD6126
inducing massive central tumour necrosis alone, the remaining,
well-perfused viable rim is the site of tumour regrowth after
treatment. Thus, it is likely that ZD6126 will be used in the clinic in
combination with conventional therapeutic modalities targeting
the tumour periphery, for example, radiation (Siemann and
Rojiani, 2001).
In summary, we have shown a strong inverse correlation of
decreased IAUC with increased tumour necrosis following
treatment with ZD6126. Measurement of IAUC by DCE MRI
should provide an unambiguous primary end point of biological
activity of antivascular therapies for clinical trial, and also a
marker for dose scheduling and timing for adjuvant therapy. As
part of the ongoing phase I study of ZD6126, the same DCE MRI
approach is being used to measure the antivascular effects in
human tumours, and in which an apparent IAUC dose–response
effect has been observed (Evelhoch et al, 2002). Changes in R  
2 ,
measured by MGRE MRI, are complex and require further
validation, but may also provide a useful biomarker of response
to antivascular therapies. ZD6126 is effective in attacking the
tumour vasculature and is a promising agent for the treatment of
cancer.
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